External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

Dipen J Parekh, Donna Pauler Ankerst, Betsy A. Higgins, Javier Hernandez, Edith Canby-Hagino, Timothy Brand, Dean A. Troyer, Robin J. Leach, Ian M. Thompson

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Objectives: To evaluate the recently developed Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator in the San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) cohort of the Early Detection Research Network, a younger and more ethnically diverse population than that in the PCPT. Methods: From 3488 SABOR participants, we identified 446 who had undergone prostate biopsy and had undergone prostate-specific antigen measurement and digital rectal examination before biopsy. Most biopsies were performed for abnormal digital rectal examination findings, a prostate-specific antigen level of more than 2.5 ng/mL, or elevated risk because of a first-degree relative with prostate cancer. We evaluated the operating characteristics of the PCPT calculator for detecting prostate cancer in this cohort of SABOR participants. Of the 446 men in this cohort, 24% were younger than 55 years of age. Results: Of the 446 men who had undergone biopsy, 148 (33.2%) had prostate cancer. The observed SABOR prostate cancer rates increased with increasing PCPT risk: 15.7%, 39.0%, 48.8%, and 100.0% for a PCPT risk calculator value of less than 25%, 25% to 50%, 50% to 75%, and greater than 75%, respectively. The PCPT risk calculator had an area under the receiver operating characteristic curve of 65.5% (95% confidence interval 60.2% to 70.8%, P <0.0001), was greater in African-American men (area under curve of 80.0%, 95% confidence interval 67.8% to 92.2%) than in other races (P = 0.02), and was not different in Hispanic men (P >0.05). Conclusions: The results of our study have shown that the PCPT risk calculator, available from the Internet and incorporating the current best panel of risk factors, is valid in other, more diverse, populations.

Original languageEnglish
Pages (from-to)1152-1155
Number of pages4
JournalUrology
Volume68
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Population
Biopsy
Digital Rectal Examination
Prostate-Specific Antigen
ROC Curve
Internet
Prostate
Biomarkers
Confidence Intervals

ASJC Scopus subject areas

  • Urology

Cite this

Parekh, D. J., Pauler Ankerst, D., Higgins, B. A., Hernandez, J., Canby-Hagino, E., Brand, T., ... Thompson, I. M. (2006). External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology, 68(6), 1152-1155. https://doi.org/10.1016/j.urology.2006.10.022

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. / Parekh, Dipen J; Pauler Ankerst, Donna; Higgins, Betsy A.; Hernandez, Javier; Canby-Hagino, Edith; Brand, Timothy; Troyer, Dean A.; Leach, Robin J.; Thompson, Ian M.

In: Urology, Vol. 68, No. 6, 01.12.2006, p. 1152-1155.

Research output: Contribution to journalArticle

Parekh, DJ, Pauler Ankerst, D, Higgins, BA, Hernandez, J, Canby-Hagino, E, Brand, T, Troyer, DA, Leach, RJ & Thompson, IM 2006, 'External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population', Urology, vol. 68, no. 6, pp. 1152-1155. https://doi.org/10.1016/j.urology.2006.10.022
Parekh DJ, Pauler Ankerst D, Higgins BA, Hernandez J, Canby-Hagino E, Brand T et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006 Dec 1;68(6):1152-1155. https://doi.org/10.1016/j.urology.2006.10.022
Parekh, Dipen J ; Pauler Ankerst, Donna ; Higgins, Betsy A. ; Hernandez, Javier ; Canby-Hagino, Edith ; Brand, Timothy ; Troyer, Dean A. ; Leach, Robin J. ; Thompson, Ian M. / External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. In: Urology. 2006 ; Vol. 68, No. 6. pp. 1152-1155.
@article{0650a29c91d74a609d2e056297211daa,
title = "External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population",
abstract = "Objectives: To evaluate the recently developed Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator in the San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) cohort of the Early Detection Research Network, a younger and more ethnically diverse population than that in the PCPT. Methods: From 3488 SABOR participants, we identified 446 who had undergone prostate biopsy and had undergone prostate-specific antigen measurement and digital rectal examination before biopsy. Most biopsies were performed for abnormal digital rectal examination findings, a prostate-specific antigen level of more than 2.5 ng/mL, or elevated risk because of a first-degree relative with prostate cancer. We evaluated the operating characteristics of the PCPT calculator for detecting prostate cancer in this cohort of SABOR participants. Of the 446 men in this cohort, 24{\%} were younger than 55 years of age. Results: Of the 446 men who had undergone biopsy, 148 (33.2{\%}) had prostate cancer. The observed SABOR prostate cancer rates increased with increasing PCPT risk: 15.7{\%}, 39.0{\%}, 48.8{\%}, and 100.0{\%} for a PCPT risk calculator value of less than 25{\%}, 25{\%} to 50{\%}, 50{\%} to 75{\%}, and greater than 75{\%}, respectively. The PCPT risk calculator had an area under the receiver operating characteristic curve of 65.5{\%} (95{\%} confidence interval 60.2{\%} to 70.8{\%}, P <0.0001), was greater in African-American men (area under curve of 80.0{\%}, 95{\%} confidence interval 67.8{\%} to 92.2{\%}) than in other races (P = 0.02), and was not different in Hispanic men (P >0.05). Conclusions: The results of our study have shown that the PCPT risk calculator, available from the Internet and incorporating the current best panel of risk factors, is valid in other, more diverse, populations.",
author = "Parekh, {Dipen J} and {Pauler Ankerst}, Donna and Higgins, {Betsy A.} and Javier Hernandez and Edith Canby-Hagino and Timothy Brand and Troyer, {Dean A.} and Leach, {Robin J.} and Thompson, {Ian M.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.urology.2006.10.022",
language = "English",
volume = "68",
pages = "1152--1155",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

AU - Parekh, Dipen J

AU - Pauler Ankerst, Donna

AU - Higgins, Betsy A.

AU - Hernandez, Javier

AU - Canby-Hagino, Edith

AU - Brand, Timothy

AU - Troyer, Dean A.

AU - Leach, Robin J.

AU - Thompson, Ian M.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Objectives: To evaluate the recently developed Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator in the San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) cohort of the Early Detection Research Network, a younger and more ethnically diverse population than that in the PCPT. Methods: From 3488 SABOR participants, we identified 446 who had undergone prostate biopsy and had undergone prostate-specific antigen measurement and digital rectal examination before biopsy. Most biopsies were performed for abnormal digital rectal examination findings, a prostate-specific antigen level of more than 2.5 ng/mL, or elevated risk because of a first-degree relative with prostate cancer. We evaluated the operating characteristics of the PCPT calculator for detecting prostate cancer in this cohort of SABOR participants. Of the 446 men in this cohort, 24% were younger than 55 years of age. Results: Of the 446 men who had undergone biopsy, 148 (33.2%) had prostate cancer. The observed SABOR prostate cancer rates increased with increasing PCPT risk: 15.7%, 39.0%, 48.8%, and 100.0% for a PCPT risk calculator value of less than 25%, 25% to 50%, 50% to 75%, and greater than 75%, respectively. The PCPT risk calculator had an area under the receiver operating characteristic curve of 65.5% (95% confidence interval 60.2% to 70.8%, P <0.0001), was greater in African-American men (area under curve of 80.0%, 95% confidence interval 67.8% to 92.2%) than in other races (P = 0.02), and was not different in Hispanic men (P >0.05). Conclusions: The results of our study have shown that the PCPT risk calculator, available from the Internet and incorporating the current best panel of risk factors, is valid in other, more diverse, populations.

AB - Objectives: To evaluate the recently developed Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator in the San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) cohort of the Early Detection Research Network, a younger and more ethnically diverse population than that in the PCPT. Methods: From 3488 SABOR participants, we identified 446 who had undergone prostate biopsy and had undergone prostate-specific antigen measurement and digital rectal examination before biopsy. Most biopsies were performed for abnormal digital rectal examination findings, a prostate-specific antigen level of more than 2.5 ng/mL, or elevated risk because of a first-degree relative with prostate cancer. We evaluated the operating characteristics of the PCPT calculator for detecting prostate cancer in this cohort of SABOR participants. Of the 446 men in this cohort, 24% were younger than 55 years of age. Results: Of the 446 men who had undergone biopsy, 148 (33.2%) had prostate cancer. The observed SABOR prostate cancer rates increased with increasing PCPT risk: 15.7%, 39.0%, 48.8%, and 100.0% for a PCPT risk calculator value of less than 25%, 25% to 50%, 50% to 75%, and greater than 75%, respectively. The PCPT risk calculator had an area under the receiver operating characteristic curve of 65.5% (95% confidence interval 60.2% to 70.8%, P <0.0001), was greater in African-American men (area under curve of 80.0%, 95% confidence interval 67.8% to 92.2%) than in other races (P = 0.02), and was not different in Hispanic men (P >0.05). Conclusions: The results of our study have shown that the PCPT risk calculator, available from the Internet and incorporating the current best panel of risk factors, is valid in other, more diverse, populations.

UR - http://www.scopus.com/inward/record.url?scp=33845312324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845312324&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2006.10.022

DO - 10.1016/j.urology.2006.10.022

M3 - Article

C2 - 17169636

AN - SCOPUS:33845312324

VL - 68

SP - 1152

EP - 1155

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -